LABFF (Laboratorios Farmaceuticos Rovi) Growth Rank: 10 (As of Jul. 11, 2026) — 25% Above Median


LABFF Laboratorios Farmaceuticos Rovi SA LABFF
93 GF Score
Price $90.61
GF Value $82.42
! 1 Warning Sign
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Growth Rank?

Laboratorios Farmaceuticos Rovi LABFF 93 Growth Rank is 10 as of Jul. 11, 2026, which is 25% above its 10-year median of 8.00. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review.

Laboratorios Farmaceuticos Rovi has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Laboratorios Farmaceuticos Rovi Growth Rank Related Terms

LABFF vs ZTS, UTHR, VTRS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laboratorios Farmaceuticos Rovi Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Growth Rank distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Growth Rank falls into.


LABFF
93GF Score
Laboratorios Farmaceuticos Rovi SA LABFF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 10 mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a Growth Rank of 10 as of Jul. 11, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 25% above median its historical median of 8.00. Over the past decade, Laboratorios Farmaceuticos Rovi's Growth Rank has ranged from 4.00 to 10.00.
Is Laboratorios Farmaceuticos Rovi's Growth Rank too high?
Laboratorios Farmaceuticos Rovi's current Growth Rank of 10 is 25% above median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 10.00. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Growth Rank compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Growth Rank of 10 can be compared against companies in the Drug Manufacturers industry. Historically, Laboratorios Farmaceuticos Rovi's own Growth Rank has ranged from 4.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Growth Rank is 10, which is 25% above median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Growth Rank of 10. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current Growth Rank is 10, which is 25% above median its 10-year median of 8.00. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Growth Rank is 10 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.

Key valuation signals for LABFF:

  • Growth Rank: 10 (25% above median its 10-year median of 8.00)
  • GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score

Get the complete analysis for LABFF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.61
Price
$82.42
GF Value